Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07116577) titled 'Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC' on Aug. 6.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Jinan Central Hospital
Condition:
mCRC
Intervention:
Radiation: Palliative radiotherapy
Drug: Iparomlimab and tuvonralimab
Drug: TAS-102
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 31, 2025
Target Sample Size: 37
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07116577
Publi...